If the treatment target is not achieved with the first
DMARD strategy, addition of a biological DMARD should be considered when poor prognostic factors are present; in the absence of poor prognostic factors, switching to another synthetic DMARD strategy should be considered 60 (85) 11 (15) 39 (78) 49 (69) 22 (31) 32 (64) 18 (36) 11. Intensive medication strategies should be considered in every patient, although patients with poor prognostic factors have more to gain.
67 (94) 4 (6) 42 (86) 7 (14) 12. If a patient is in persistent remission, after having tapered GCs, one can consider tapering biological DMARDs, especially if this treatment is combined with a synthetic DMARD 54 (76) 17 (24) 37 (76) 12 (24) 13. In cases of sustained long-term remission, cautious titration of synthetic DMARD dose could be considered, as a shared decision between patient and doctor 61 (86) 10 (14) 43 (88) Are you following the recommendations? N (%) 55 (79) 15 (21) 31 (66) 16 (34) 1. The primary target for treatment of rheumatoid arthritis should be a state of clinical remission.
65 (93) 5 (7) 41 (93) 3 (7) 2. Clinical remission is defined as the absence of signs and symptoms of significant inflammatory disease activity.
68 (97) 2 (3) 39 (89) 5 (11) 3. While remission should be a clear target, based on available evidence low disease activity may be an acceptable alternative
67 (96) 3 (4) 42 (95) 2 (5) 4. Until the desired treatment target is reached, drug therapy should be adjusted at least every 3 months.
65 (93) 5 (7) 37 (84) 7 (16) 5. Measures of disease activity must be obtained and documented regularly, as frequently as monthly for patients with high/moderate disease activity or less frequently (such as every 3-6 months) for patients in sustained low disease activity or remission 60 (86) 10 (14) 31 (70) 13 (30) 6. The use of validated composite measures of disease activity, which include joint assessments, is needed in routine clinical practice to guide treatment decisions.
65 (93) 5 (7) 39 (89) 5 (11) 7. Structural changes and functional impairment should be considered when making clinical decisions, in addition to assessing 64 (91) 6 (9) 41 (93) 3 (7) 8. The desired treatment target should be maintained throughout the remaining course of the disease.
65 (93) 5 (7) 37 (84) 7 (16) 9. The choice of the (composite) measure of disease activity and the level of the target value may be influenced by consideration of co-morbidities, patient factors and drug-related risks.
67 (96) 3 (4) 38 (86) 6 (14) 10. The patient has to be appropriately informed about the treatment target and the strategy planned to reach this target under the supervision of the rheumatologist.
65 (93) 5 (7) 41 (93) 3 (7)
*LF=lost to follow-up Attachment III: baseline characteristics for patients in the IRIS study Table 1 . Baseline characteristics for patients in the IRIS study *
Total patients, n=378
Female, n (%) 300 (82) Age, mean (SD) 55 (14) 
